Analyst Reco. I-Mab BOERSE MUENCHEN

Equities

0VY

US44975P1030

Real-time BOERSE MUENCHEN Other stock markets 12:44:17 28/06/2024 am IST			5-day change	1st Jan Change
1.58 ^EUR	-2.47%		-2.41%	-2.99%

06/06	I-Mab Appoints Phillip Dennis as Chief Medical Officer	CI
05/06	I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating	18/03	MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating	15/03	MT
Needham Trims I-Mab Price Target to $23 From $24, Maintains Buy Rating	25/23/25	MT
HC Wainwright Adjusts Price Target on I-Mab to $18 From $25, Maintains Buy Rating	18/23/18	MT
Needham Lowers Price Target on I-Mab to $24 From $33, Maintains Buy Rating	03/23/03	MT
Piper Sandler Adjusts Price Target on I-Mab to $25 From $30, Maintains Overweight Rating	03/23/03	MT
HC Wainwright Adjusts Price Target on I-Mab to $25 From $45, Maintains Buy Rating	03/23/03	MT
I-Mab Says Combination Treatment for Myelodysplastic Syndrome Showed Overall Response Rate of 86.7% in Phase 2 Trial	12/22/12	MT
HC Wainwright Adjusts I-Mab's Price Target to $45 From $70, Maintains Buy Rating	31/22/31	MT
Needham Adjusts I-Mab's Price Target to $33 From $41, Reiterates Buy Rating	31/22/31	MT
Piper Sandler Adjusts I-Mab's Price Target to $30 From $35, Reiterates Overweight Rating	31/22/31	MT
Needham Lowers I-Mab's Price Target to $41 From $72, Maintains Buy Rating	17/22/17	MT
HC Wainwright Adjusts I-Mab's Price Target to $70 From $80, Keeps Buy Rating	31/22/31	MT
Piper Sandler Adjusts I-Mab's Price Target to $35 From $80, Reiterates Overweight Rating	31/22/31	MT
Needham Adjusts I-Mab's Price Target to $72 From $85, Reiterates Buy Rating	31/22/31	MT
HC Wainwright Adjusts I-Mab's Price Target to $80 from $95, Keeps Buy Rating	30/22/30	MT
Piper Sandler Adjusts I-Mab's Price Target to $80 From $90, Reiterates Overweight Rating	30/22/30	MT
SWS Research Starts I-Mab at Buy with $96 Price Target	09/21/09	MT
Needham Adjusts Price Target on I-Mab to $85 from $83, Keeps Buy Rating	01/21/01	MT
I MAB : HC Wainwright Adjusts I-Mab's Price Target to $95 from $75, Keeps Buy Rating	01/21/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. I-Mab BOERSE MUENCHEN

Equities

0VY

US44975P1030

Analyst Reco.

Filters